CMS-D017
/ China Medical System
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 23, 2026
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
(ChiCTR)
- P1 | N=88 | Sponsor: Peking University Third Hospital; Peking University Third Hospital
New P1 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases
April 09, 2026
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
(clinicaltrials.gov)
- P1 | N=88 | Recruiting | Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Complement-mediated Rare Disorders • Hematological Disorders • Nephrology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Renal Disease
March 11, 2026
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
(clinicaltrials.gov)
- P1 | N=88 | Not yet recruiting | Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd.
First-in-human • New P1 trial • Complement-mediated Rare Disorders • Hematological Disorders • Nephrology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Renal Disease
January 30, 2026
China Medical System Holdings has received approval from China’s National Medical Products Administration to begin clinical trials in healthy participants for CMS-D017, a self-developed, orally administered, small-molecule inhibitor of complement factor B intended to treat paroxysmal nocturnal hemoglobinuria (PNH).
(TipRanks)
New trial • Paroxysmal Nocturnal Hemoglobinuria
1 to 4
Of
4
Go to page
1